Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3276-3285

  Kanehira, Mitsugu ^a,b   Katagiri, Toyomasa ^a   Shimo, Arata ^a   Takata, Ryo ^a   Shuin, Taro ^c   Miki, Tsuneharu ^d   Fujioka, Tomoaki ^b   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; COMPLEMENTARY DNA; MESSENGER RNA; MPHOSPH1 ANTIGEN; PROTEIN REGULATOR OF CYTOKINESIS 1; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MPHOSPH1 PROTEIN, HUMAN; PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN FUNCTION; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL DEATH; CELL STRAIN 3T3; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MOUSE; MULTINUCLEAR CELL; NONHUMAN; NORTHERN BLOTTING; ORGAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; BLADDER TUMOR; CELL FRACTIONATION; CELL STRAIN COS1; CERCOPITHECUS; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MICE; NIH 3T3 CELLS; ONCOGENES; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SUBCELLULAR FRACTIONS; TRANSFECTION; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 34248203246     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3748     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Sternberg CN. The treatment of advanced bladder cancer. Ann Oncol 1995;6:113-26.
3. Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005;92:645-50.
4. Fagg SL, Dawson-Edwards P, Hughes MA, Latief TN, Rolfe EB, Fielding JW. cis-Diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. Br J Urol 1984;56:296-300.
5. Raghavan D, Pearson B, Coorey G, et al. Intravenous cis-platinum for invasive bladder cancer. Safety and feasibility of a new approach. Med J Aust 1984;140:276-8.
6. Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 2005;48:60-8.
7. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.
8. Splinter TA, Scher HI, Denis L, et al.; European Organization for Research on Treatment of Cancer-Genitourinary Group. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 1992;147:606-8.
9. Vaughn DJ. Review and outlook for the role of paclitaxel in urothelial carcinoma Semin Oncol 1999;26:117-22.
10. Petricoin EF III, Hackett JL, Lesko LJ, et al. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet 2002;32 Suppl:474-9.
11. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PD2-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen having an oncogenic activity in breast cancer. Cancer Res 2006;66:9186-95.
12. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40.
13. Taniuchi K, Nakagawa H, Hosokawa M, et al. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases K. Cancer Res 2005;65:3092-9.
14. Taniuchi K, Nakagawa H, Nakamura T, et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res 2005;65:105-12.
15. Anazawa Y, Nakagawa H, Furihata M, et al. Analysis of gene-expression profiles after γ irradiation of normal human fibroblasts. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Iβ/SET. Cancer Res 2005;65:4578-86.
16. Ashida S, Furihata M, Katagiri T, et al. Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res 2006;12:2767-73.
17. Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y. Identification of PDZK4, a novel human gene with PDZ domains, that is up-regulated in synovial sarcomas. Oncogene 2004;23:5551-7.
18. Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. Oncogene 2005;24:6201-12.
19. Togashi A, Katagiri T, Ashida S, et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 2005;65:4817-26.
20. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36.
21. Saito-Hisaminato A, Katagiri T, Kakiuchi S, et al. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002;9:35-45.
22. Kitahara O, Furukawa Y, Tanaka T, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 2001;61:3544-9.
23. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the h-catenin/T-cell factor complex. Cancer Res 2003;63:6116-20.
24. Kamimoto T, Zama T, Aoki R, Muro Y, Hagiwara M. Identification of a novel kinesin-related protein, KRMP1, as a target for mitotic peptidyl-prolyl isomerase Pin1. J Biol Chem 2001;276:37520-8.
25. Mollinari C, Kleman JP, Jiang W, et al. PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol 2002;157:1175-86.
26. Jiang W, Jimenez G, Wells JN, et al. PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol Cell 1998;2:877-85.
27. Abaza A, Soleilhac JM, Westendorf J, et al. M phase phosphoprotein 1 is a human plus-end-directed kinesin-related protein required for cytokinesis. J Biol Chem 2003;278:27844-52.
28. Kurasawa Y, Earnshaw WC, Mochizuki Y, Dohmae N, Todokoro K. Essential roles of KIF4 and its binding partner PRC1 in organized central spindle midzone formation. EMBO J 2004;23:3237-48.
29. Zhu C, Jiang W. Cell cycle-dependent translocation of PRC1 on the spindle by Kif4 is essential for midzone formation and cytokinesis. Proc Natl Acad Sci U S A 2005;10:343-8.
30. Gruneberg U, Neef R, Li X, et al. KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 2006;172:363-72.
31. Mollinari C, Kleman JP, Saoudi Y, et al. Ablation of PRC1 by small interfering RNA demonstrates that cytokinetic abscission requires a central spindle bundle in mammalian cells, whereas completion of furrowing does not. Mol Biol Cell 2005;16:1043-55.